Security Investigation
DexCom, Inc. (NasdaqGS: DXCM)
53 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2025 to file lead plaintiff applications in a securities class action lawsuit against DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM), if they purchased or otherwise acquired the securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
DexCom and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 18, 2025, Hunterbrook published a report addressing the Company, entitled “Dexcom’s Fatal Flaws,” revealing that issues and health risks posed by the Company’s adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees. Specifically, the Hunterbrook report found that “G7 users have been hospitalized and died” following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and the Company’s willingness to cut corners to meet margins.
On this news, the price of DexCom’s shares fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.
If you purchased securities of DexCom and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is Prime v. DexCom, Inc., et al., No. 25-cv-08912.